Glucotoxicity in Peritoneal Dialysis-Solutions for the Solution!

Advances in Chronic Kidney Disease

Volumn 14, Issue 3, 2007, Pages 269-278

  Holmes, Clifford J ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

additives; Glucose; osmotic agents; peritoneal dialysis; solution

Indexed keywords

GLUCOSE; ICODEXTRIN; LOW MOLECULAR WEIGHT HEPARIN; OSMOTIC AGENT; SULODEXIDE; XYLITOL;

ACIDOSIS; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; GLUCOSE ABSORPTION; HEMODIALYSIS PATIENT; HUMAN; HYPEROSMOLALITY; MEMBRANE STRUCTURE; METABOLISM; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ULTRAFILTRATION; UREMIA;

DIALYSIS SOLUTIONS; FEMALE; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; KIDNEY FAILURE, CHRONIC; MALE; PERITONEAL DIALYSIS; PROGNOSIS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 34250855123     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2007.03.009     Document Type: Article

References (58)

1. Martis L., Topley N., and Holmes C.J. Conventional and newer peritoneal dialysis solutions. In: Owen W.F., Pereira J.G., and Sayegh M.H. (Eds). Dialyis and Transplantation: A Companion to Brenner and Rector's The Kidney (2000), WB Saunders, Philadelphia, PA 179-198
2. Tjiong H.L., van den Berg J.W., Wattimena J.L., et al. Dialysate as food: Combined amino acid and glucose dialysate improves protein anabolism in renal failure patients on automated peritoneal dialysis. J Am Soc Nephrol 16 (2005) 1486-1493
3. Burkart J. Metabolic consequences of peritoneal dialysis. Semin Dial 17 (2004) 498-504
4. Lindholm B., and Bergstrom J. Nutritional management of patients undergoing peritoneal dialysis. In: Nolph K. (Ed). Peritoneal Dialysis (1989), Kluwer, Dordrecht, The Netherlands 230-260
5. Prichard S.S. Management of hyperlipidemia in patients on peritoneal dialysis: Current approaches. Kidney Int 70 suppl 103 (2006) S115-S117
6. Pennell P., Rojas C., Asif A., et al. Managing metabolic complications of peritoneal dialysis. Clin Nephrol 62 (2004) 35-43
7. Nordfors L., Heimburger O., Lonnqvist F., et al. Fat tissue accumulation during peritoneal dialysis is associated with a polymorphism in uncoupling protein 2. Kidney Int 57 (2000) 1713-1719
8. Snyder J.J., Foley R.N., Gilbertson D.T., et al. Body size and outcomes on peritoneal dialysis in the United States. Kidney Int 64 (2003) 1838-1844
9. Abbott K.C., Glanton C.W., Trespalacios F.C., et al. Body mass index, dialysis modality, and survival: Analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II Study. Kidney Int 65 (2004) 597-605
10. McDonald S.P., Collins J.F., and Johnson D.W. Obesity is associated with worse peritoneal dialysis outcomes in the Australia and New Zealand patient populations. J Am Soc Nephrol 14 (2003) 2894-2901
11. Axelsson J., Qureshi A.R., Suliman M.E., et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr 80 (2004) 1222-1229
12. Delarue J., and Maingourd C. Acute metabolic effects of dialysis fluids during CAPD. Am J Kidney Dis 37 (2001) S103-S107
13. Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 54 (2005) 1615-1625
14. Brownlee M., and Hirsch I.B. Glycemic variability: A hemoglobin A1c-independent risk factor for diabetic complications. JAMA 295 (2006) 1707-1708
15. Selby N.M., Fonseca S., Hulme L., et al. Hypertonic glucose-based peritoneal dialysate is associated with higher blood pressure and adverse haemodynamics as compared with icodextrin. Nephrol Dial Transplant 20 (2005) 1848-1853
16. Vonesh E.F., Snyder J.J., Foley R.N., et al. Mortality studies comparing peritoneal dialysis and hemodialysis: What do they tell us?. Kidney Int 70 suppl 103 (2006) S3-S11
17. Mortier S., Lameire N.H., and De Vriese A.S. The effects of peritoneal dialysis solutions on peritoneal host defense. Perit Dial Int 24 (2004) 123-138
18. Diaz-Buxo J.A., and Gotloib L. Agents that modulate peritoneal membrane structure and function. Perit Dial Int 27 (2007) 16-30
19. Davies S.J., Brown E.A., Frandsen N.E., et al. Longitudinal membrane function in functionally anuric patients treated with APD: Data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 67 (2005) 1609-1615
20. Davies S.J. Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int 66 (2004) 2437-2445
21. Johansson A.C., and Haraldsson B. Physiological properties of the peritoneum in an adult peritoneal dialysis population over a three-year period. Perit Dial Int 26 (2006) 482-489
22. La Milia V., Pozzoni P., Virga G., et al. Peritoneal transport assessment by peritoneal equilibration test with 3.86% glucose: A long-term prospective evaluation. Kidney Int 69 (2006) 927-933
23. Asci G., Ozkahya M., Duman S., et al. Volume control associated with better cardiac function in long-term peritoneal dialysis patients. Perit Dial Int 26 (2006) 85-88
24. Medcalf J.F., Harris K.P., and Walls J. What place diuretics in long-term CAPD?. Nephrol Dial Transplant 13 (1998) 2193-2194
25. Fischbach M., Desprez P., Donnars F., et al. Optimization of CCPD prescription in children using peritoneal equilibration test. Adv Perit Dial 10 (1994) 307-309
26. Holmes C., and Mujais S. Glucose sparing in peritoneal dialysis: Implications and metrics. Kidney Int 70 suppl 103 (2006) S104-S109
27. Bajo M.A., Selgas R., del Peso G., et al. Use of icodextrin for diurnal exchange in patients undergoing automatic peritoneal dialysis: Comparison with glucose solutions. Nefrologia 22 (2002) 348-355
28. Bredie S.J., Bosch F.H., Demacker P.N., et al. Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial Int 21 (2001) 275-281
29. Davies S.J., Woodrow G., Donovan K., et al. Icodextrin improves the fluid status of peritoneal dialysis patients: Results of a double-blind randomized controlled trial. J Am Soc Nephrol 14 (2003) 2338-2344
30. Sisca S., and Maggiore U. Beneficial effect of icodextrin on the hypertriglyceridemia of CAPD patients. Perit Dial Int 22 (2002) 727-729
31. Amici G., Orrasch M., Da Rin G., et al. Hyperinsulinism reduction associated with icodextrin treatment in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 17 (2001) 80-83
32. Furuya R., Odamaki M., Kumagai H., et al. Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients. Nephrol Dial Transplant 21 (2006) 494-498
33. Marshall J., Jennings P., Scott A., et al. Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS). Kidney Int 64 (2003) 1480-1486
34. Johnson D.W., Arndt M., O'Shea A., et al. Icodextrin as salvage therapy in peritoneal dialysis patients with refractory fluid overload. BMC Nephrol 2 (2001) 2
35. Martikainen T., Teppo A.M., Gronhagen-Riska C., et al. Benefit of glucose-free dialysis solutions on glucose and lipid metabolism in peritoneal dialysis patients. Blood Purif 23 (2005) 303-310
36. Selby N.M., Fialova J., Burton J.O., et al. The haemodynamic and metabolic effects of hypertonic-glucose and amino-acid-based peritoneal dialysis fluids. Nephrol Dial Transplant 22 (2007) 870-879
37. Van V., Schoonjans R.S., Struijk D.G., et al. Influence of dialysate on gastric emptying time in peritoneal dialysis patients. Perit Dial Int 22 (2002) 32-38
38. Jones M., Hagen T., Boyle C.A., et al. Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: Results of a multicenter outpatient study. Am J Kidney Dis 32 (1998) 761-769
39. Fernando S.K., Santacroce S., and Finkelstein F. Two daytime icodextrin exchanges. J Am Soc Nephrol 17 (2006) 278A
40. Fontan M.P., Rodriguez-Carmona A., Garcia-Lopez E., et al. Icodextrin based nocturnal automated peritoneal dialysis allows sustained ultrafiltration while reducing glucose load: A crossover study. J Am Soc Nephrol 17 (2006) 278A
41. Van Biesen W., Vanholder R., and Lameire N. Recent developments in osmotic agents for peritoneal dialysis. Adv Ren Replace Ther 5 (1998) 218-231
42. Gokal R. Osmotic agents in peritoneal dialysis. Contrib Nephrol 85 (1990) 126-133
43. Dienes H.P., Gerharz C.D., Wagner R., et al. Accumulation of hydroxyethyl starch (HES) in the liver of patients with renal failure and portal hypertension. J Hepatol 3 (1986) 223-227
44. Mistry C.D., and Gokal R. The use of glucose polymer (icodextrin) in peritoneal dialysis: an overview. Perit Dial Int 14 suppl 3 (1994) S158-S161
45. Freida P.F., Galach M., Divino Filho J.C., et al. Combination of crystalloid (glucose) and colloid (icodextrin) osmotic agents markedly enhances peritoneal fluid and solute transport during the long APD dwell. Perit Dial Int (2007) (in press)
46. Jenkins S.B., and Wilke M.E. An exploratory study of a novel peritoneal combination dialysate (1.36% glucose/7.5% icodextrin), demonstrating improved ultrafiltration compared to either component studies alone. Perit Dial Int 23 (2003) 475-480
47. Faller B., Shockley T., Genestier S., et al. Polyglucose and amino acids: Preliminary results. Perit Dial Int 17 suppl 2 (1997) S63-S67
48. Van Biesen W., Boer W., De Greve B., et al. A randomized clinical trial with a 0.6% amino acid/1.4% glycerol peritoneal dialysis solution. Perit Dial Int 24 (2004) 222-230
49. Bazzato G., Coli U., Landini S., et al. Xylitol as osmotic agent in CAPD: An alternative to glucose for uremic diabetic patients?. Trans Am Soc Artif Intern Organs 28 (1982) 280-286
50. Mingrone G. Carnitine in type 2 diabetes. Ann N Y Acad Sci 1033 (2004) 99-107
51. Kosan C., Sever L., Arisoy N., et al. Carnitine supplementation improves apolipoprotein B levels in pediatric peritoneal dialysis patients. Pediatr Nephrol 18 (2003) 1184-1188
52. Sjoland J.A., Pedersen R.S., Jespersen J., et al. Intraperitoneal heparin ameliorates the systemic inflammatory response in PD patients. Nephron Clin Pract 100 (2005) c105-c110
53. Sjoland J.A., Smith Pedersen R., Jespersen J., et al. Intraperitoneal heparin reduces peritoneal permeability and increases ultrafiltration in peritoneal dialysis patients. Nephrol Dial Transplant 19 (2004) 1264-1268
54. Nasstrom B., Stegmayr B., Gupta J., et al. A single bolus of a low molecular weight heparin to patients on haemodialysis depletes lipoprotein lipase stores and retards triglyceride clearing. Nephrol Dial Transplant 20 (2005) 1172-1179
55. Bazzato G., Fracasso A., Gambaro G., et al. Use of glycosaminoglycans to increase efficiency of long-term continuous peritoneal dialysis. Lancet 346 (1995) 740-741
56. Fracasso A., Baggio B., Ossi E., et al. Glycosaminoglycans prevent the functional and morphological peritoneal derangement in an experimental model of peritoneal fibrosis. Am J Kidney Dis 33 (1999) 105-110
57. Fracasso A., Baggio B., Masiero M., et al. Effect of oral treatment with the glycosaminoglycan sulodexide on peritoneal transport in CAPD patients. Perit Dial Int 23 (2003) 595-599
58. Gambaro G., Kinalska I., Oksa A., et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: The Di.N.A.S. randomized trial. J Am Soc Nephrol 13 (2002) 1615-1625